News
SXTP
1.610
-1.83%
-0.030
Weekly Report: what happened at SXTP last week (0615-0619)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/16 21:06
Top Executive Makes Bold Move With Fresh Buy in Pharma Stock
TipRanks · 06/16 02:05
60 Degrees Pharma CEO Geoffrey Dow acquires 7,350 common shares worth $10,130.24
PUBT · 06/15 20:51
Weekly Report: what happened at SXTP last week (0608-0612)?
Weekly Report · 06/15 10:21
60 Degrees Pharmaceuticals sings FSU deal to scale Australian chestnut extract
Seeking Alpha · 06/11 13:22
60 Degrees executes patent licensing agreement with Florida State
TipRanks · 06/11 13:01
60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription Uses
Benzinga · 06/11 12:13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/11 12:05
60 Degrees Pharma signs exclusive Florida State University patent license for Australian chestnut extract supplement use
PUBT · 06/11 12:04
60 DEGREES PHARMACEUTICALS SIGNS EXCLUSIVE PATENT LICENSE AGREEMENT WITH FLORIDA STATE UNIVERSITY FOR NON-PRESCRIPTION USE OF AUSTRALIAN CHESTNUT EXTRACT AS A BOTANICAL SUPPLEMENT
Reuters · 06/11 12:03
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/09 21:06
60 Degrees Pharmaceuticals announces annual shareholder meeting
PUBT · 06/08 21:15
Weekly Report: what happened at SXTP last week (0601-0605)?
Weekly Report · 06/08 10:17
60 Degrees details tafenoquine priority review voucher strategy
TipRanks · 06/03 22:14
60 Degrees Pharmaceuticals Says Co. May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028
Benzinga · 06/03 21:08
60 DEGREES PHARMACEUTICALS - MAY SUBMIT NDA FOR TAFENOQUINE TO FDA BEFORE END OF Q1 2028 - SEC FILING
Reuters · 06/03 20:58
Weekly Report: what happened at SXTP last week (0525-0529)?
Weekly Report · 06/01 10:22
60 Degrees announces early enrollment of first patient in trial of tafenoquine
TipRanks · 05/26 14:57
60 Degrees Pharma enrolls first patient in tafenoquine babesiosis trial in US Northeast hospitals
PUBT · 05/26 12:08
More
Webull provides a variety of real-time SXTP stock news. You can receive the latest news about 60 degrees pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SXTP
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.